As 1 paradigm-defining example of precision medicine, activating mutations in the EGFR are associated with high response rates to EGFR-directed tyrosine kinase inhibitors (TKIs) in non–small cell lung cancer (NSCLC) (1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.